Results 211 to 220 of about 345,077 (288)

miR-629-3p affects postmenopausal osteoporosis through targeted regulation of BACH1. [PDF]

J Orthop Surg Res
Yun D, Zhang J, Ha S, Xiao J, Yan C.
europepmc   +1 more source

Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future. [PDF]

Pharmaceuticals (Basel)
Papapoulos SE, Makras P.
europepmc   +1 more source

Research Trends in Immunomodulatory Therapy for Postmenopausal Osteoporosis: A Bibliometric Analysis. [PDF]

Orthop Surg
Yi S, Liu J, Chen H, Deng Z, Zhang Y, Luo Y, Li Y, Tang W.   +7 more
europepmc   +1 more source

Follistatin-like protein 1 (FSTL1) modulates bone remodeling and attenuates bone loss in a mouse model of postmenopausal osteoporosis. [PDF]

JBMR Plus
Yuan H, Chen BR, Han FX, Huang K, Jia ZH, Dong YY, Bo L.   +6 more
europepmc   +1 more source

Sijing Pill modulates PGE2/EP4/PI3K-AKT pathway via gut-bone axis to treat postmenopausal osteoporosis. [PDF]

Front Microbiol
Zhu X, Li Y, Meng X, Jiang T, Li C, Zhu X, Yin Z, Guo J, Su X.   +8 more
europepmc   +1 more source

LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis. [PDF]

J Endocr Soc
Krecipro-Nizinska E, Pluskiewicz W, Supronik J, Szeles P, Petit-Frere C, Varone E, Ferrari S, Valter I.   +7 more
europepmc   +1 more source

Designed bone-targeting ROS-responsive nanoplatform for precision glycolysis inhibition in postmenopausal osteoporosis. [PDF]

Bioact Mater
Wu Q, Miao J, Chen Y, Yang Y, Liang H, Yu C, Wang C, Tu Y, Wu Y, Xu Y, Yang X, Kwan KYH, Shi C, Wang X, Xu J, Jin H.   +15 more
europepmc   +1 more source

Cost-effectiveness analysis of Chinese patent medicines for the treatment of postmenopausal osteoporosis in China. [PDF]

Front Public Health
Wang C, Lin X, Liu J, Zhang Y, You R.
europepmc   +1 more source